A neuroprotective peptide designed for the prevention of brain damage following ischemic events such as stroke and cardiac arrest. It includes two functional domains for crossing cell membranes and inhibiting CaMKII, a target for neuroprotection.

Neurexis focuses on the preclinical development of tatCN19o, coordinating studies for treatment of ischemic injury in the brain.